0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Journal Articles

in Drug Therapy
 221-240 of 522 Articles
Editorial | 
Mitchell H. Katz, MD
JAMA Intern Med. 2013;173(3):178. doi:10.1001/jamainternmed.2013.1838.

Editor's Correspondence | 
Bruno Michel, PharmD, PhD; Bapiste Quelennec, PharmD; Emmanuel Andres, MD, PhD
JAMA Intern Med. 2013;173(3):246-247. doi:10.1001/jamainternmed.2013.1235.

Editor's Correspondence | 
Mónica Tarapués, MD; Gloria Cereza, MD; Albert Figueras, MD
JAMA Intern Med. 2013;173(3):247-248. doi:10.1001/jamainternmed.2013.1614.

Editor's Correspondence | 
Beatrice A. Golomb, MD, PhD; Sabrina Koperski, BS
JAMA Intern Med. 2013;173(3):247-248. doi:10.1001/jamainternmed.2013.2113.

Original Investigation |  FREE
Aaron S. Kesselheim, MD, JD, MPH; Alexander S. Misono, MD, MBA; William H. Shrank, MD, MSHS; et al.
JAMA Intern Med. 2013;173(3):202-208. doi:10.1001/2013.jamainternmed.997.

Original Investigation |  FREE
Neda Ratanawongsa, MD, MPH; Andrew J. Karter, PhD; Melissa M. Parker, MS; et al.
JAMA Intern Med. 2013;173(3):210-218. doi:10.1001/jamainternmed.2013.1216.

Invited Commentary | 
Aanand D. Naik, MD
JAMA Intern Med. 2013;173(3):218-219. doi:10.1001/jamainternmed.2013.1229.

Viewpoint | 
B. Joseph Guglielmo, PharmD
JAMA Intern Med. 2013;173(3):184-185. doi:10.1001/jamainternmed.2013.1405.

Invited Commentary | 
Lawrence X. Yu, PhD; Gregory P. Geba, MD, MPH
JAMA Intern Med. 2013;173(3):208-209. doi:10.1001/jamainternmed.2013.2283.

Special Article | 
Jonas B. Green, MD, MPH, MSHS; Joseph S. Ross, MD, MHS; Cynthia A. Jackevicius, PharmD, MSc; et al.
JAMA Intern Med. 2013;173(3):229-232. doi:10.1001/jamainternmed.2013.1529.

Research Letters |  FREE
Eric G. Campbell, PhD; Genevieve Pham-Kanter, PhD; Christine Vogeli, PhD; et al.
JAMA Intern Med. 2013;173(3):237-239. doi:10.1001/jamainternmed.2013.1539.

Invited Commentary | 
Brian K. Alldredge, PharmD; Steven R. Kayser, PharmD
JAMA Intern Med. 2013;173(3):233-234. doi:10.1001/jamainternmed.2013.1777.

Perspectives |  FREE
Rita F. Redberg, MD, MSc
JAMA Intern Med. 2013;173(3):179. doi:10.1001/jamainternmed.2013.3378.

Original Investigation |  FREE
Tara Gomes, MHSc; Donald A. Redelmeier, MD; David N. Juurlink, MD, PhD; et al.
JAMA Intern Med. 2013;173(3):196-201. doi:10.1001/2013.jamainternmed.733.
Includes: Supplemental Content

Research Letters |  FREE
Maya Vijayaraghavan, MD, MAS; Joanne Penko, MS, MPH; David R. Bangsberg, MD, MPH; et al.
JAMA Intern Med. 2013;173(3):235-237. doi:10.1001/jamainternmed.2013.1576.
Includes: Supplemental Content

Editor's Correspondence | 
Douglas MacKay, ND
JAMA Intern Med. 2013;173(2):166-167. doi:10.1001/2013.jamainternmed.1028.

Editor's Correspondence | 
Donald M. Marcus, MD; Arthur P. Grollman, MD
JAMA Intern Med. 2013;173(2):166-167. doi:10.1001/jamainternmed.2013.1747.

Correction |  FREE
JAMA Intern Med. 2013;173(1):14. doi:10.1001/jamainternmed.2013.3143.

Editor's Correspondence | 
Michael Pazianas, MD
JAMA Intern Med. 2013;173(1):79-80. doi:10.1001/2013.jamainternmed.753.

Editor's Correspondence | 
Raphael P. H. Meier, MD; Rene Rizzoli, MD; Robin E. Peter, MD
JAMA Intern Med. 2013;173(1):79-80. doi:10.1001/jamainternmed.2013.1238.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA
Viewpoint  | 
Evaluation of Flibanserin Science and Advocacy at the FDA
Walid F. Gellad, MD, MPH; Kathryn E. Flynn, PhD; G. Caleb Alexander, MD, MS
JAMA Psychiatry
Original Investigation  | 
Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia A Prospective Dopamine D2/3 Receptor Occupancy Study
Ariel Graff-Guerrero, MD, PhD; Tarek K. Rajji, MD; Benoit H. Mulsant, MD, MS; et al.
JAMA Oncology
From The JAMA Network  | 
Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy
Jennifer A. Lo, BA; David E. Fisher, MD, PhD; Keith T. Flaherty, MD
JAMA Pediatrics
Viewpoint  | 
Global Collaboration to Develop New and Existing Drugs for Neonates
Jonathan M. Davis, MD; Mark A. Turner, MB, PhD, MRCPCH